iX Biopharma's (SGX:42C) net loss attributable to equity holders widened 196% to SG$5.0 million during the fiscal fourth quarter ended June 30 from SG$1.7 million a year earlier.
Loss per share came in at SG$0.0048 compared with SG$0.0019 in the year-ago period, according to a Friday filing with the Singapore Exchange.
Revenue fell 7% year over year to SG$2.1 million from SG$2.2 million.
Shares of the healthcare provider were down nearly 9% Monday morning.